This study aimed to determine if sodium-glucose co-transporter-2 inhibitors (SGLT2i) use in diabetic patients leads to erythrocytosis and increases the incidence of arterial and venous thrombosis events. This is a retrospective cohort study using records from over 50 U.S. healthcare organizations. Adults with type 2 diabetes who received SGLT2i therapy were compared to those on… Continue reading #Erythrocytosis and #thromboembolic risks associated with #SGLT2 inhibitors in type 2 diabetes
Tag: SGLT2
GLP-1RA and SGLT2i Medications for Type 2 #Diabetes and #Alzheimer Disease and Related Dementias
Importance The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed.Objective To assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D).Design, Setting, and Participants This target trial emulation study used electronic… Continue reading GLP-1RA and SGLT2i Medications for Type 2 #Diabetes and #Alzheimer Disease and Related Dementias
Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
The aim of this study was to determine the impact at 5 years of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) on liver histopathology and clinical features. In this retrospective study, the histological impacts at 5 years after the start of SGLT2i in NAFLD with T2DM were… Continue reading Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
Effects of #SGLT-2 inhibitors on serum #uric acid in patients with T2DM: A systematic review and network meta-analysis
The present study aims to determine the effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes mellitus (T2DM) in Asia. MethodsPubMed, CENTRAL, Embase and Cochrane Library databases were searched for randomized controlled trials (RCTs) of SGLT-2 inhibitors in patients with T2DM up to July… Continue reading Effects of #SGLT-2 inhibitors on serum #uric acid in patients with T2DM: A systematic review and network meta-analysis
Incidence of adverse #cardiovascular events in type 2 #diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
Increased incidence of hospitalization for heart failure (HHF) among patients with diabetes is increasingly being reported. We investigated the incidence of adverse cardiovascular events including HHF among patients with type 2 diabetes mellitus, and the potential clinical improvement with sodium–glucose cotransporter 2 inhibitors (SGLT2i) using a contemporary administrative claims database from a large governmental district… Continue reading Incidence of adverse #cardiovascular events in type 2 #diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
EUGLYCEMIC DIABETIC #KETOACIDOSIS WITH #COVID-19 INFECTION IN PATIENTS WITH TYPE 2 DIABETES TAKING #SGLT2 INHIBITORS
Diabetes mellitus is associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Diabetic ketoacidosis (DKA) has also been reported to occur with this virus. A cluster of cases of euglycemic DKA (euDKA) was identified in patients with type 2 diabetes mellitus using sodium-glucose cotransporter-2 inhibitors (SGLT2is) who developed SARS-CoV-2 infection.. ..Five… Continue reading EUGLYCEMIC DIABETIC #KETOACIDOSIS WITH #COVID-19 INFECTION IN PATIENTS WITH TYPE 2 DIABETES TAKING #SGLT2 INHIBITORS
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious #renal events: Scandinavian cohort study
..Cohort of 29 887 new users of SGLT2 inhibitors (follow-up time: dapagliflozin 66.1%; empagliflozin 32.6%; canagliflozin 1.3%) and 29 887 new users of an active comparator, dipeptidyl peptidase-4 inhibitors, matched 1:1 on the basis of a propensity score with 57 variables. Mean follow-up time was 1.7 (SD 1.0) years. ..The mean age of the study population was… Continue reading Use of sodium-glucose co-transporter 2 inhibitors and risk of serious #renal events: Scandinavian cohort study
Assessing the Risk for #Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study
Hyperuricemia is common in patients with type 2 diabetes mellitus and is known to cause gout. Sodium–glucose cotransporter-2 (#SGLT2) inhibitors prevent glucose reabsorption and lower serum uric acid levels.. ..The gout incidence rate was lower among patients prescribed an SGLT2 inhibitor (4.9 events per 1000 person-years) than those prescribed a GLP1 agonist (7.8 events per… Continue reading Assessing the Risk for #Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study
2 Medical News 